Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Exenatide's rapid anti-inflammatory effect may inhibit atherosclerosis

Exenatide, a drug commonly prescribed to help patients with type 2 diabetes improve blood sugar control, also has a powerful and rapid anti-inflammatory effect, a University at Buffalo study has shown.

3 Nov 2011

Researchers use diabetes drug to permanently reprogram insulin-producing cells

Pediatric researchers who tested newborn animals with an existing human drug used in adults with diabetes report that this drug, when given very early in life, prevents diabetes from developing in adult animals. If this finding can be repeated in humans, it may become a way to prevent at-risk infants from developing type 2 diabetes.

3 Nov 2011

New laser technique could create tissue scaffolds, microneedles

In the emerging field of tissue engineering, scientists encourage cells to grow on carefully designed support scaffolds. The ultimate goal is to create living structures that might one day be used to replace lost or damaged tissue, but the manufacture of appropriately detailed scaffolds presents a significant challenge that has kept most tissue engineering applications confined to the research lab.

3 Nov 2011

DexCom signs research and development agreement with Roche

Roche Diagnostics U.S., with its business unit Roche Diabetes Care, a leader in blood glucose monitoring and insulin delivery systems, and DexCom, Inc., a leader in continuous glucose monitoring systems, announced today that they have signed a research and development agreement.

From Roche Sequencing and Life Science 3 Nov 2011

Resveratrol holds key to reducing obesity and associated risks: Study

A new study shows that when taken regularly a natural compound known as resveratrol, found in red wine and grapes, mulberries and peanuts, can offer similar benefits to low-calorie diets and endurance training.

2 Nov 2011

Isis commences ISIS-GCGRRx and ISIS-GCCRRx Phase 1 studies for type 2 diabetes

Isis Pharmaceuticals, Inc. announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.

2 Nov 2011

Glyphosine can prevent development of type 1 diabetes

Researchers at the University of Colorado School of Medicine have found a specific molecule that can prevent the development of type 1 diabetes in mice and has a similar effect on human cells from diabetic patients.

2 Nov 2011

Positive results from DARA's DB959 Phase 1b study on type 2 diabetes

DARA BioSciences, Inc., announces the positive results from a successfully completed Phase 1b clinical study for DB959, its peroxisome proliferator activated receptor (PPAR)-delta/gamma agonist, a non-TZD oral drug in development for the treatment of type 2 diabetes.

2 Nov 2011

Renowned obstetrician receives March of Dimes 2011 Agnes Higgins award

A highly renowned obstetrician, professor and researcher who showed that babies born to obese and diabetic women have a higher risk of becoming overweight and developing diabetes or other metabolic health problems later in life, received the March of Dimes 2011 Agnes Higgins award for outstanding achievement in the field of maternal-fetal nutrition.

31 Oct 2011

FDA approves Medtronic's LGS IDE for clinical trial to treat Type 1 diabetes

In our continued commitment to develop an artificial pancreas, Medtronic, Inc. today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal in-home clinical trial protocol for the ASPIRE study of the MiniMed Paradigm System featuring Low Glucose Suspend (LGS) automation.

From Medtronic 29 Oct 2011

Specific metabolic disturbances precede children's progression to Type 1 diabetes

New potential avenues for early disease detection and prevention: A study led by Matej Orešič from VTT Technical Research Centre of Finland suggests that autoimmune diabetes is preceded by diminished gut microbial diversity of the Clostridium leptum subgroup, elevated plasma leptin and enhanced glucose-stimulated insulin secretion.

29 Oct 2011

Scientists describe how protein acts as courier in cell signaling pathways

Normal development, from fertilized egg to adult organism, depends on each cell receiving proper instructions from its environment. In response to such incoming information, receptors on a cell's surface send signals to the nucleus that tweak gene expression and control cellular function.

28 Oct 2011

Adult stem cells can reshape our organs in response to environmental change

A new study from University of California, Berkeley, researchers demonstrates that adult stem cells can reshape our organs in response to changes in the body and the environment, a finding that could have implications for diabetes and obesity.

28 Oct 2011

Innovative trial project of MD-Logic Artificial Pancreas takes place in Israel

At the initiative, and under the leadership of specialists in the Jesse Z and Sara Lea Shaffer Institute for Endocrinology and Diabetes, National Center of Childhood Diabetes, Schneider Children's Medical Center, an innovative trial project of the MD-Logic Artificial Pancreas (MDLAP) has successfully taken place in Israel.

27 Oct 2011

International diabetes researchers to engineer artificial pancreas system

The National Institutes for Health (NIH) have awarded $4.5 million to a group of international diabetes researchers to engineer an artificial pancreas system that will monitor and adapt to the body's complex real-time changes in behavior and physiology.

27 Oct 2011

Insulin resistance paradox

Obesity and insulin resistance are almost inevitably associated with increases in lipid accumulation in the liver, a serious disease that can deteriorate to hepatitis and liver failure. A real paradox in understanding insulin resistance is figuring out why insulin-resistant livers make more fat. Insulin resistance occurs when the body does a poor job of lowering blood sugars.

27 Oct 2011

Holtorf Medical Group opens new affiliate center in King of Prussia, Pennsylvania

Holtorf Medical Group, California's leading integrative, evidence-based medical facility, is pleased to announce the opening of its newest affiliate center, Garabedian Medical Clinic in King of Prussia, Pennsylvania.

24 Oct 2011

U-M researchers to study new approach in halting downward spiral of diabetes

University of Michigan Health System researchers will use a $3.5 million federal grant to study a new approach in halting the downward spiral of diabetes.

24 Oct 2011

Janssen announces FDA label update approval for PREZISTA HIV tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA (darunavir) tablets to include 192-week data from the ARTEMIS study.

22 Oct 2011

Inhibition of miR-33a/b suppresses triglyceride levels, increases HDL-C cholesterol

Researchers at NYU Langone Medical Center today announce findings published in the October 20 issue of Nature that show for the first time the inhibition of both microRNA-33a and microRNA-33b (miR-33a/b) with chemically modified anti-miR oligonucleotides markedly suppress triglyceride levels and cause a sustained increase in high density lipoprotein cholesterol (HDL-C) "good" cholesterol.

21 Oct 2011